Jeffrey Summe
Family Medicine · Lynnwood, WANPI 1861409732
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 720 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,512 and has fallen 91.1% since, to $400 in 2025. Among family medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 720 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Orexo US, Inc.$2K
- Novo Nordisk$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Gilead$1K
- AbbVie$936
- plus $6K from 33 others
What the payments were for
- Food & beverage$14,287100%
- Education$520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,339 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $9,730 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 36 | $6,706 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 72 | $1,967 |
| Omeprazole | 19 | $415 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 20 | $293 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 14 | $265 |
| Ondansetron OdtOndansetron | 17 | $252 |
| Hydroxychloroquine Sulfate | 12 | $242 |
| Buprenorphine Hcl | 17 | $217 |
| Amlodipine Besylate | 20 | $208 |
| Oxycodone Hcl | 26 | $176 |
| Cyclobenzaprine Hcl | 13 | $169 |
| Tramadol Hcl | 13 | $62 |
| Azithromycin | 16 | $50 |
| Eszopiclone | 12 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $192 | $9,73015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Lynnwood
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
- Cynthia CoteMaple Valley$66K
- Greg LedgerwoodBrewster$66K
- Daniel RivasBurien$50K
- Kent WalkerSumner$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.